American Journal of Pathology
American Journal of Pathology
5 years ago

Neurotrophin Receptors TrkA, p75NTR, and Sortilin are Increased and Targetable in Thyroid Cancer

Neurotrophin receptors are emerging targets in oncology, but their clinicopathological significance in thyroid cancer is unclear. Here, the neurotrophin tyrosine receptor kinase TrkA (also called NTRK1), the common neurotrophin receptor p75NTR, and the pro-neurotrophin receptor sortilin were analyzed by immunohistochemistry in a cohort of thyroid cancers (n=128), and compared with adenomas and normal thyroid tissues (n=62). TrkA was detected in 20% of thyroid cancers, compared with none of the benign samples (P = 0.0007). TrkA expression was independent of histological subtypes but associated with lymph node metastasis (P = 0.0148), suggesting the involvement of TrkA in tumor invasiveness. Also, nerves in the tumor microenvironment were positive for TrkA. P75NTR was overexpressed in anaplastic thyroid cancers compared to papillary and follicular subtypes (P < 0.0001). Sortilin was overexpressed in thyroid cancers, compared to benign thyroid tissues (P < 0.0001). Neurotrophin receptor expression was confirmed in a panel of thyroid cancer cell lines, at the mRNA and protein levels. Functional investigations using the anaplastic thyroid cancer cell line CAL-62 demonstrated that siRNA against TrkA, p75NTR, and sortilin decreased cell survival and cell migration through decreased SRC and ERK activation. Similar results were obtained with another anaplastic cell line, 8505c, except for p75NTR, which was not expressed. Together, these data reveal TrkA, p75NTR, and sortilin as potential therapeutic targets in thyroid cancer.

Publisher URL: www.sciencedirect.com/science

DOI: S0002944017304923

You might also like
Discover & Discuss Important Research

Keeping up-to-date with research can feel impossible, with papers being published faster than you'll ever be able to read them. That's where Researcher comes in: we're simplifying discovery and making important discussions happen. With over 19,000 sources, including peer-reviewed journals, preprints, blogs, universities, podcasts and Live events across 10 research areas, you'll never miss what's important to you. It's like social media, but better. Oh, and we should mention - it's free.

  • Download from Google Play
  • Download from App Store
  • Download from AppInChina

Researcher displays publicly available abstracts and doesn’t host any full article content. If the content is open access, we will direct clicks from the abstracts to the publisher website and display the PDF copy on our platform. Clicks to view the full text will be directed to the publisher website, where only users with subscriptions or access through their institution are able to view the full article.